ASMB Relative Valuation
ASMB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ASMB is overvalued; if below, it's undervalued.
Historical Valuation
Assembly Biosciences Inc (ASMB) is now in the Undervalued zone, suggesting that its current forward PS ratio of 17.60 is considered Undervalued compared with the five-year average of -2.37. The fair price of Assembly Biosciences Inc (ASMB) is between 34.13 to 50.61 according to relative valuation methord. Compared to the current price of 30.68 USD , Assembly Biosciences Inc is Undervalued By 10.1%.
Relative Value
Fair Zone
34.13-50.61
Current Price：30.68
10.1%
Undervalued
-15.92
PE
1Y
3Y
5Y
-6.28
EV/EBITDA
Assembly Biosciences Inc. (ASMB) has a current EV/EBITDA of -6.28. The 5-year average EV/EBITDA is -0.58. The thresholds are as follows: Strongly Undervalued below -4.37, Undervalued between -4.37 and -2.47, Fairly Valued between 1.32 and -2.47, Overvalued between 1.32 and 3.21, and Strongly Overvalued above 3.21. The current Forward EV/EBITDA of -6.28 falls within the Strongly Undervalued range.
-4.16
EV/EBIT
Assembly Biosciences Inc. (ASMB) has a current EV/EBIT of -4.16. The 5-year average EV/EBIT is -0.14. The thresholds are as follows: Strongly Undervalued below -3.24, Undervalued between -3.24 and -1.69, Fairly Valued between 1.40 and -1.69, Overvalued between 1.40 and 2.95, and Strongly Overvalued above 2.95. The current Forward EV/EBIT of -4.16 falls within the Strongly Undervalued range.
17.60
PS
Assembly Biosciences Inc. (ASMB) has a current PS of 17.60. The 5-year average PS is 11.15. The thresholds are as follows: Strongly Undervalued below -37.85, Undervalued between -37.85 and -13.35, Fairly Valued between 35.65 and -13.35, Overvalued between 35.65 and 60.15, and Strongly Overvalued above 60.15. The current Forward PS of 17.60 falls within the Historic Trend Line -Fairly Valued range.
-7.78
P/OCF
Assembly Biosciences Inc. (ASMB) has a current P/OCF of -7.78. The 5-year average P/OCF is -1.11. The thresholds are as follows: Strongly Undervalued below -4.80, Undervalued between -4.80 and -2.95, Fairly Valued between 0.73 and -2.95, Overvalued between 0.73 and 2.57, and Strongly Overvalued above 2.57. The current Forward P/OCF of -7.78 falls within the Strongly Undervalued range.
-7.71
P/FCF
Assembly Biosciences Inc. (ASMB) has a current P/FCF of -7.71. The 5-year average P/FCF is -1.41. The thresholds are as follows: Strongly Undervalued below -5.05, Undervalued between -5.05 and -3.23, Fairly Valued between 0.41 and -3.23, Overvalued between 0.41 and 2.23, and Strongly Overvalued above 2.23. The current Forward P/FCF of -7.71 falls within the Strongly Undervalued range.
Assembly Biosciences Inc (ASMB) has a current Price-to-Book (P/B) ratio of 2.92. Compared to its 3-year average P/B ratio of 2.69 , the current P/B ratio is approximately 8.52% higher. Relative to its 5-year average P/B ratio of 1.87, the current P/B ratio is about 56.25% higher. Assembly Biosciences Inc (ASMB) has a Forward Free Cash Flow (FCF) yield of approximately -10.45%. Compared to its 3-year average FCF yield of -45.10%, the current FCF yield is approximately -76.83% lower. Relative to its 5-year average FCF yield of -59.10% , the current FCF yield is about -82.32% lower.
2.92
P/B
Median3y
2.69
Median5y
1.87
-10.45
FCF Yield
Median3y
-45.10
Median5y
-59.10
Competitors Valuation Multiple
The average P/S ratio for ASMB's competitors is 77.50, providing a benchmark for relative valuation. Assembly Biosciences Inc Corp (ASMB) exhibits a P/S ratio of 17.60, which is -77.29% above the industry average. Given its robust revenue growth of 57.62%, this premium appears sustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of ASMB increased by 124.05% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -3.66 to -7.54.
The secondary factor is the Revenue Growth, contributed 57.62%to the performance.
Overall, the performance of ASMB in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
ALXO
ALX Oncology Holdings Inc
1.25USD
5.93%
HSPO
Horizon Space Acquisition I Corp
12.03USD
-23.42%
MLSS
Milestone Scientific Inc
0.287USD
0.00%
CODA
Coda Octopus Group Inc
10.08USD
1.10%
SHIM
Shimmick Corp
3.48USD
2.05%
CTOR
Citius Oncology Inc
1.14USD
-0.87%
VOR
Vor Biopharma Inc
12.84USD
-5.31%
ORMP
Oramed Pharmaceuticals Inc
3.46USD
5.81%
ALOT
AstroNova Inc
9.16USD
0.66%
Frequently Asked Questions
Is Assembly Biosciences Inc (ASMB) currently overvalued or undervalued?
Assembly Biosciences Inc (ASMB) is now in the Undervalued zone, suggesting that its current forward PS ratio of 17.60 is considered Undervalued compared with the five-year average of -2.37. The fair price of Assembly Biosciences Inc (ASMB) is between 34.13 to 50.61 according to relative valuation methord. Compared to the current price of 30.68 USD , Assembly Biosciences Inc is Undervalued By 10.10% .
What is Assembly Biosciences Inc (ASMB) fair value?
ASMB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Assembly Biosciences Inc (ASMB) is between 34.13 to 50.61 according to relative valuation methord.
How does ASMB's valuation metrics compare to the industry average?
The average P/S ratio for ASMB's competitors is 77.50, providing a benchmark for relative valuation. Assembly Biosciences Inc Corp (ASMB) exhibits a P/S ratio of 17.60, which is -77.29% above the industry average. Given its robust revenue growth of 57.62%, this premium appears sustainable.
What is the current P/B ratio for Assembly Biosciences Inc (ASMB) as of Jan 08 2026?
As of Jan 08 2026, Assembly Biosciences Inc (ASMB) has a P/B ratio of 2.92. This indicates that the market values ASMB at 2.92 times its book value.
What is the current FCF Yield for Assembly Biosciences Inc (ASMB) as of Jan 08 2026?
As of Jan 08 2026, Assembly Biosciences Inc (ASMB) has a FCF Yield of -10.45%. This means that for every dollar of Assembly Biosciences Inc’s market capitalization, the company generates -10.45 cents in free cash flow.
What is the current Forward P/E ratio for Assembly Biosciences Inc (ASMB) as of Jan 08 2026?
As of Jan 08 2026, Assembly Biosciences Inc (ASMB) has a Forward P/E ratio of -15.92. This means the market is willing to pay $-15.92 for every dollar of Assembly Biosciences Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Assembly Biosciences Inc (ASMB) as of Jan 08 2026?
As of Jan 08 2026, Assembly Biosciences Inc (ASMB) has a Forward P/S ratio of 17.60. This means the market is valuing ASMB at $17.60 for every dollar of expected revenue over the next 12 months.